SCYNEXIS, Inc. filed a current report on Form 8-K on September 22, 2026, disclosing the appointment of Steven K. Burke, M.D., as a new member of its Board of Directors, effective September 18, 2026.

Key Highlights

  • New Director: Steven K. Burke, M.D., was appointed to the SCYNEXIS Board of Directors effective September 18, 2026.
  • Committee Role: Dr. Burke was also appointed as a member of the Nominating and Corporate Governance Committee.
  • Annual Cash Retainer: Dr. Burke will receive an annual retainer of $45,000, plus $5,000 for his committee service.
  • Initial Equity Grants: Dr. Burke received an initial stock option to purchase 5,750 shares at an exercise price of $4.46, and an initial restricted stock unit grant to acquire 5,750 shares.
  • Annual Equity: Each year, Dr. Burke is eligible for an annual grant of options to purchase 2,875 shares and restricted stock units to acquire 2,875 shares, vesting in full on the one-year anniversary of the grant date.
  • Term: Dr. Burke will serve until SCYNEXIS's 2027 Annual Meeting of Stockholders and until his successor is duly elected and qualified.

SCYNEXIS Board Expansion: Burke Appointment and Compensation Terms

According to the filing, the Board of Directors of SCYNEXIS, Inc. (NASDAQ:SCYX) appointed Steven K. Burke, M.D., as a director on September 18, 2026. The filing states that Dr. Burke's term runs until the company's 2027 Annual Meeting of Stockholders and until his successor is duly elected and qualified. He was simultaneously appointed to the Nominating and Corporate Governance Committee.

The filing details Dr. Burke's compensation package as a non-employee director. In addition to cash retainers totaling $50,000 annually ($45,000 base plus $5,000 for committee service), he received an initial stock option grant to purchase 5,750 shares at an exercise price of $4.46 per share, which the filing states equals the closing price of SCYNEXIS common stock on September 18, 2026. One-third of the option vests on the one-year anniversary of the grant date, with the remaining shares vesting in equal monthly installments over the following 24 months, subject to continued service. He also received an initial restricted stock unit grant for 5,750 shares, with one-third vesting each year on the anniversary of the grant date, also subject to continued service.

The filing further discloses that Dr. Burke will be eligible for annual equity grants under the company's Non-Employee Director Compensation Policy, currently consisting of options to purchase 2,875 shares and restricted stock units for 2,875 shares, both vesting in full on the one-year grant anniversary. SCYNEXIS also entered into its standard indemnification agreement with Dr. Burke. The filing states there is no arrangement or understanding between Dr. Burke and any other person regarding his selection, no family relationship with other directors or executive officers, and that the company is not aware of any transaction involving Dr. Burke requiring disclosure under Item 404(a) of Regulation S-K.

What Was Disclosed

SCYNEXIS disclosed the appointment of Steven K. Burke, M.D., to its Board of Directors and Nominating and Corporate Governance Committee, along with the full terms of his director compensation, effective September 18, 2026.